Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma
Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma
复制标题
抗缺氧诱导因子脯氨酰羟化酶 3 的自身抗体是肾细胞癌的潜在血清学标志物
DOI：
10.1007/s00432-010-0940-6
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
T.
中科院分区：
文献类型：
--
作者：
Tanaka;T.;Kitamura;H.;Torigoe;T.;Hirohashi;Y.;Masumori;N.;Sato;N. and Tsukamoto;T.
目的验证血清抗缺氧诱导因子脯氨酰羟化酶-3（PHD 3）自身抗体作为肾细胞癌（RCC）血清学标志物的有效性。方法收集22例原发性RCC患者的血清标本和手术切除的肿瘤组织标本，其中15例行根治性肾切除术，7例行肾部分切除术。在肿瘤切除前获得术前血清样品。在肿瘤切除后至少1个月从17名患者获得术后血清样品。还从26名健康志愿者获得血清样品。结果肾细胞癌患者血清抗PHD 3抗体滴度（0.610 ± 0.023）明显高于健康对照组（0.591 ± 0.031，P = 0.0001）;以0.599为界值，预测肾细胞癌的敏感性、特异性和阳性率分别为86.4%、57.7%和63.3%。17例患者手术切除后血清抗PHD 3抗体滴度均较术前下降（0.622 ± 0.023vs.0.580 ± 0.024，P = 0.0003）。
PurposeTo verify the efficacy of a serum autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 (PHD3) as a serological marker for RCC.MethodsSerum samples and surgically resected tumor tissue specimens were obtained from 22 patients with primary RCC, 15 of whom underwent radical nephrectomy and 7 partial nephrectomy. Preoperative serum samples were obtained just before tumor resection. Postoperative serum samples were obtained from 17 patients at least 1 month after tumor removal. Serum samples were also obtained from 26 healthy volunteers. Titers of the anti-PHD3 antibody (Ab) were determined by enzyme-linked immunosorbent assay.ResultsSerum anti-PHD3 Ab titers were significantly higher in patients with RCC than in healthy volunteers (0.610 ± 0.023 vs. 0.591 ± 0.031,P= 0.0001). Using a cutoff point of 0.599, sensitivity, specificity, and positivity for prediction of RCC were 86.4, 57.7, and 63.3%, respectively. In all 17 patients, titers of serum anti-PHD3 were decreased after the surgical resection compared with those before operation (0.622 ± 0.023 vs. 0.580 ± 0.024,P= 0.0003).ConclusionsThe present study suggests that the anti-PHD3 Ab may be a novel serological marker for RCC and the titer may reflect the tumor burden in each individual.